PT2588130T - Entrega de agentes terapêuticos no cns - Google Patents

Entrega de agentes terapêuticos no cns

Info

Publication number
PT2588130T
PT2588130T PT117990358T PT11799035T PT2588130T PT 2588130 T PT2588130 T PT 2588130T PT 117990358 T PT117990358 T PT 117990358T PT 11799035 T PT11799035 T PT 11799035T PT 2588130 T PT2588130 T PT 2588130T
Authority
PT
Portugal
Prior art keywords
therapeutic agents
cns delivery
cns
delivery
therapeutic
Prior art date
Application number
PT117990358T
Other languages
English (en)
Inventor
Shahrokh Zahra
Calias Pericles
Mccauley Thomas
Powell Jan
Pan Jing
Pfeifer Richard
Charnas Lawrence
Leah Wright Teresa
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45352777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2588130(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of PT2588130T publication Critical patent/PT2588130T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
PT117990358T 2010-06-25 2011-06-25 Entrega de agentes terapêuticos no cns PT2588130T (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US36078610P 2010-07-01 2010-07-01
US38786210P 2010-09-29 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US201161495268P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
PT2588130T true PT2588130T (pt) 2016-11-25

Family

ID=45352777

Family Applications (6)

Application Number Title Priority Date Filing Date
PT117990374T PT2585104T (pt) 2010-06-25 2011-06-25 Métodos e composições de arilsulfatase a para a administração no snc
PT191925080T PT3626257T (pt) 2010-06-25 2011-06-25 Métodos e composições de arilsulfatase a para a administração no snc
PT117990358T PT2588130T (pt) 2010-06-25 2011-06-25 Entrega de agentes terapêuticos no cns
PT161791504T PT3103469T (pt) 2010-06-25 2011-06-25 Administração de agentes terapêuticos no snc
PT191926799T PT3626258T (pt) 2010-06-25 2011-06-25 Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase
PT117990366T PT2593131T (pt) 2010-06-25 2011-06-25 Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT117990374T PT2585104T (pt) 2010-06-25 2011-06-25 Métodos e composições de arilsulfatase a para a administração no snc
PT191925080T PT3626257T (pt) 2010-06-25 2011-06-25 Métodos e composições de arilsulfatase a para a administração no snc

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT161791504T PT3103469T (pt) 2010-06-25 2011-06-25 Administração de agentes terapêuticos no snc
PT191926799T PT3626258T (pt) 2010-06-25 2011-06-25 Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase
PT117990366T PT2593131T (pt) 2010-06-25 2011-06-25 Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase

Country Status (24)

Country Link
US (14) US9814764B2 (pt)
JP (21) JP6250616B2 (pt)
CN (4) CN105233277B (pt)
AR (6) AR082025A1 (pt)
BR (1) BR112012033214B1 (pt)
CA (1) CA3171308A1 (pt)
CL (7) CL2012003654A1 (pt)
DK (3) DK3626257T3 (pt)
ES (3) ES2895655T3 (pt)
HK (2) HK1214149A1 (pt)
HR (3) HRP20211660T1 (pt)
HU (6) HUE055963T2 (pt)
LT (3) LT3103469T (pt)
MX (1) MX354776B (pt)
NZ (2) NZ702803A (pt)
PE (8) PE20170938A1 (pt)
PL (1) PL2588130T3 (pt)
PT (6) PT2585104T (pt)
RS (3) RS62620B1 (pt)
RU (1) RU2761342C2 (pt)
SI (3) SI3626257T1 (pt)
SM (1) SMT201600385B (pt)
TW (8) TW201212936A (pt)
UA (2) UA125060C2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2661042C (en) 2006-08-18 2012-12-11 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
ES2650689T3 (es) 2010-06-25 2018-01-19 Shire Human Genetic Therapies, Inc. Administración de agentes terapéuticos al sistema nervioso central
US20220133863A1 (en) * 2010-06-25 2022-05-05 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
CA2805413A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of heparan n-sulfatase
KR102094094B1 (ko) 2010-06-25 2020-03-27 샤이어 휴먼 지네틱 테라피즈 인크. 아릴설파타제 a의 cns 전달을 위한 방법들 및 조성물들
HUE055963T2 (hu) 2010-06-25 2022-01-28 Shire Human Genetic Therapies Eljárások és kompozíciók iduronát-2-szulfáz központi idegrendszerbe történõ leadásához
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CA2859988A1 (en) * 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
KR20220119187A (ko) * 2013-05-15 2022-08-26 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3292206B8 (en) 2015-05-07 2022-02-09 Takeda Pharmaceutical Company Limited Glucocerebrosidase gene therapy for parkinson's disease
UA123704C2 (uk) * 2015-12-30 2021-05-19 Грін Кросс Корпорейшн Спосіб лікування синдрому хантера
KR20180114199A (ko) * 2016-02-24 2018-10-17 바이오마린 파머수티컬 인크. 표적화된 치료적 리소좀 효소 융합 단백질들, 관련 제형들 및 이의 용도들
BR112018071156A2 (pt) 2016-04-15 2019-03-12 The Trustees Of The University Of Pennsylvania terapia de gene para tratar mucopolissacaridose tipo ii
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
EP3760220A4 (en) * 2018-02-28 2022-01-19 Seikagaku Corporation PACKAGING AND ITS MANUFACTURING PROCESS
CN108534695A (zh) * 2018-05-04 2018-09-14 无锡恩特卫自动化检测设备有限公司 一种基于机器视觉系统的瓶塞漏酒检测方法及装置
WO2020004368A1 (ja) 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
JP7253770B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
JP7253771B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
CN116916947A (zh) 2020-10-14 2023-10-20 戴纳立制药公司 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法
CN113283465B (zh) * 2021-04-02 2022-04-29 电子科技大学 一种弥散张量成像数据分析方法及装置
CN115116623A (zh) * 2022-06-28 2022-09-27 深圳市儿童医院 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133001A (en) * 1959-11-26 1964-05-12 Muset Pedro Puig Stabilization of enzymes
US4743265A (en) 1986-04-23 1988-05-10 Dij Catheter Corp Articulated catheter placement device
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
ATE206308T1 (de) * 1993-02-02 2001-10-15 Xoma Technology Ltd Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
DE69808402T2 (de) 1997-08-22 2003-07-03 Seikagaku Kogyo Co Ltd Arzneimittel zur Behandlung von durch Hernie gestörter intervertebraler Bandscheibe
ES2677343T3 (es) 1998-12-07 2018-08-01 Genzyme Corporation Tratamiento de la enfermedad de Pompe
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6368315B1 (en) 1999-06-23 2002-04-09 Durect Corporation Composite drug delivery catheter
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US20020099025A1 (en) * 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
US6866844B2 (en) * 2002-11-07 2005-03-15 Biomarin Pharmaceutical Inc. Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003032727A1 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003068159A2 (en) 2002-02-11 2003-08-21 Wake Forest University Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
ES2367257T3 (es) * 2002-04-25 2011-10-31 Shire Human Genetic Therapies, Inc. Tratamiento de deficit de alfa-galactosidasa a.
CA2487815A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
US20040248262A1 (en) 2003-01-22 2004-12-09 Koeberl Dwight D. Constructs for expressing lysomal polypeptides
PT2444102E (pt) 2003-01-31 2015-09-17 Sinai School Medicine Terapia combinada para o tratamento de distúrbios de deficiência proteica
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
JP5036302B2 (ja) 2003-02-10 2012-09-26 ティオー − ビービービー ホールディング ベスローテン フェンノートシャップ 炎症状態下に血液脳関門で示差的（ｄｉｆｆｅｒｅｎｔｉａｌｌｙ）に発現される核酸
JP5624256B2 (ja) 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
NZ576986A (en) * 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
WO2005074888A2 (en) 2004-02-03 2005-08-18 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
WO2005077093A2 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
JP4914224B2 (ja) 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
BRPI0510271A (pt) * 2004-06-15 2007-10-30 Baxter Int aplicações ex-vivo agentes terapêuticos microparticulados
JP2008516190A (ja) * 2004-08-11 2008-05-15 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド 酵素に基づく時間・温度インジケーター
IL165334A0 (en) * 2004-11-22 2006-01-15 Mediwound Ltd Debriding composition from bromelain and methods of producing same
JPWO2006121199A1 (ja) * 2005-05-11 2008-12-18 日本ケミカルリサーチ株式会社 脂質小胞体組成物
US7964617B2 (en) 2005-06-08 2011-06-21 Amicus Therapeutics, Inc. Methods for treating parkinsons disease and parkinsonism
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
MX361816B (es) 2006-02-09 2018-12-17 Genzyme Corp Suministro intraventricular lento.
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
PL2631242T3 (pl) 2006-04-04 2023-03-20 Takeda Pharmaceutical Company Limited Sposób zatężania polipeptydu
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
WO2008070769A1 (en) * 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
CA2680189A1 (en) 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
WO2009017005A1 (ja) 2007-07-27 2009-02-05 Sharp Kabushiki Kaisha 移動局装置、基地局装置、通信システム及びプログラム
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
EP2223934B1 (en) * 2007-11-14 2012-10-03 Institute Of Microbiology, Chinese Academy Of Sciences Polypeptides for inhibiting influenza virus infection
SG10201604258YA (en) 2007-11-30 2016-07-28 Abbvie Biotechnology Ltd Anti-tnf antibody formulations
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2009131698A2 (en) 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
AU2009244148B2 (en) 2008-05-07 2014-10-09 Biomarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US8436489B2 (en) 2009-06-29 2013-05-07 Lightsail Energy, Inc. Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange
HUE055963T2 (hu) 2010-06-25 2022-01-28 Shire Human Genetic Therapies Eljárások és kompozíciók iduronát-2-szulfáz központi idegrendszerbe történõ leadásához
CA2805413A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of heparan n-sulfatase
MX2013000324A (es) 2010-06-25 2013-02-01 Shire Human Genetic Therapies Tratamiento del sindrome de sanfilippo tipo b.
MX2020001395A (es) 2010-06-25 2022-03-24 Shire Human Genetic Therapies Composiciones y su uso para suministro de iduronato-2-sulfatasa al sistema nervioso central.
US20110318324A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of b-galactocerebrosidase
ES2650689T3 (es) * 2010-06-25 2018-01-19 Shire Human Genetic Therapies, Inc. Administración de agentes terapéuticos al sistema nervioso central
KR102094094B1 (ko) 2010-06-25 2020-03-27 샤이어 휴먼 지네틱 테라피즈 인크. 아릴설파타제 a의 cns 전달을 위한 방법들 및 조성물들
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
US8580922B2 (en) * 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
EP2793922B1 (en) * 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a

Also Published As

Publication number Publication date
CL2012003657A1 (es) 2013-04-19
JP2017214434A (ja) 2017-12-07
SI3626257T1 (sl) 2021-12-31
JP6285409B2 (ja) 2018-02-28
TWI602573B (zh) 2017-10-21
LT3626258T (lt) 2021-12-10
US20130295077A1 (en) 2013-11-07
JP2019006826A (ja) 2019-01-17
JP6797876B2 (ja) 2020-12-09
JP2021181489A (ja) 2021-11-25
RS62620B1 (sr) 2021-12-31
RU2017125281A (ru) 2019-01-31
US20170042978A1 (en) 2017-02-16
US9220677B2 (en) 2015-12-29
JP7359827B2 (ja) 2023-10-11
BR112012033214B1 (pt) 2020-11-03
PT3626258T (pt) 2021-10-19
HUE031036T2 (en) 2017-06-28
LT3103469T (lt) 2021-03-25
PT2585104T (pt) 2019-10-30
RU2018113327A (ru) 2019-03-01
JP2023062114A (ja) 2023-05-02
US10456454B2 (en) 2019-10-29
NZ702803A (en) 2017-05-26
US20230026836A1 (en) 2023-01-26
US20220133862A1 (en) 2022-05-05
TW201815411A (zh) 2018-05-01
JP2018002735A (ja) 2018-01-11
SMT201600385B (it) 2017-03-08
US20180071212A1 (en) 2018-03-15
JP2023099216A (ja) 2023-07-11
US11260112B2 (en) 2022-03-01
DK3626258T3 (da) 2021-09-20
HRP20211520T1 (hr) 2021-12-24
RS62520B1 (sr) 2021-11-30
CL2017002488A1 (es) 2017-12-15
US20200405825A1 (en) 2020-12-31
TWI669128B (zh) 2019-08-21
US20230165942A1 (en) 2023-06-01
US20170042977A1 (en) 2017-02-16
CL2012003655A1 (es) 2013-04-19
PT2593131T (pt) 2019-10-30
HK1218719A1 (zh) 2017-03-10
HUE046409T2 (hu) 2020-02-28
RS61683B1 (sr) 2021-05-31
US20140271598A1 (en) 2014-09-18
PT3626257T (pt) 2021-11-12
JP2016040337A (ja) 2016-03-24
PE20130578A1 (es) 2013-05-19
TW201206465A (en) 2012-02-16
US20200046810A1 (en) 2020-02-13
TW201825111A (zh) 2018-07-16
CN106139133B (zh) 2020-12-04
JP6522072B2 (ja) 2019-05-29
JP6938456B2 (ja) 2021-09-22
ES2896060T3 (es) 2022-02-23
TWI698252B (zh) 2020-07-11
US9814764B2 (en) 2017-11-14
PE20130648A1 (es) 2013-07-03
ES2858726T3 (es) 2021-09-30
CA3171308A1 (en) 2011-12-29
PE20130637A1 (es) 2013-06-13
NZ702800A (en) 2017-03-31
JP2016040335A (ja) 2016-03-24
JP2021167341A (ja) 2021-10-21
AR081679A1 (es) 2012-10-10
HK1214149A1 (zh) 2016-07-22
US11065308B2 (en) 2021-07-20
CL2012003654A1 (es) 2013-06-14
CN105233277B (zh) 2019-01-01
PE20180130A1 (es) 2018-01-18
CL2012003656A1 (es) 2013-07-19
RU2018137304A (ru) 2019-03-21
JP7448507B2 (ja) 2024-03-12
JP2020079297A (ja) 2020-05-28
US20180085438A1 (en) 2018-03-29
MX354776B (es) 2018-03-20
TW201212936A (en) 2012-04-01
TWI609694B (zh) 2018-01-01
AR081680A1 (es) 2012-10-10
DK3626257T3 (da) 2021-11-08
JP2016094451A (ja) 2016-05-26
CL2020000468A1 (es) 2020-09-04
CN104857504A (zh) 2015-08-26
JP2016041755A (ja) 2016-03-31
ES2895655T3 (es) 2022-02-22
HUE052944T2 (hu) 2021-05-28
US10646554B2 (en) 2020-05-12
SI3626258T1 (sl) 2021-11-30
JP2020079244A (ja) 2020-05-28
JP2018002734A (ja) 2018-01-11
JP6522073B2 (ja) 2019-05-29
JP6466538B2 (ja) 2019-02-06
AR082025A1 (es) 2012-11-07
AR081681A1 (es) 2012-10-10
JP2016037504A (ja) 2016-03-22
CN106139133A (zh) 2016-11-23
RU2018113327A3 (pt) 2021-07-21
SI3103469T1 (sl) 2021-04-30
JP2022024176A (ja) 2022-02-08
HUE056884T2 (hu) 2022-03-28
UA125743C2 (uk) 2022-06-01
JP2019031575A (ja) 2019-02-28
JP2019038853A (ja) 2019-03-14
HRP20211660T1 (hr) 2022-02-04
US20160158324A1 (en) 2016-06-09
JP7087175B2 (ja) 2022-06-20
PT3103469T (pt) 2021-03-04
HUE046856T2 (hu) 2020-03-30
RU2018137304A3 (pt) 2022-02-22
US11471516B2 (en) 2022-10-18
US11065307B2 (en) 2021-07-20
AR081678A1 (es) 2012-10-10
JP2023052868A (ja) 2023-04-12
PE20170938A1 (es) 2017-07-13
TW201701899A (zh) 2017-01-16
US20190183984A1 (en) 2019-06-20
PE20130579A1 (es) 2013-05-19
JP2020079298A (ja) 2020-05-28
CN105233277A (zh) 2016-01-13
JP6898909B2 (ja) 2021-07-07
RU2017125281A3 (pt) 2020-11-09
RU2761342C2 (ru) 2021-12-07
DK3103469T3 (en) 2021-02-22
TW202112391A (zh) 2021-04-01
TW202337489A (zh) 2023-10-01
PE20130589A1 (es) 2013-05-19
CL2016003159A1 (es) 2017-05-12
TWI790444B (zh) 2023-01-21
LT3626257T (lt) 2021-12-10
CN105664142A (zh) 2016-06-15
HUE055963T2 (hu) 2022-01-28
AR081677A1 (es) 2012-10-10
HRP20210298T1 (hr) 2021-04-16
PL2588130T3 (pl) 2017-09-29
UA125060C2 (uk) 2022-01-05
JP2021167340A (ja) 2021-10-21
US20200113981A1 (en) 2020-04-16
JP6346162B2 (ja) 2018-06-20
MX2013000321A (es) 2013-04-03
BR112012033214A2 (pt) 2017-05-23
JP6250616B2 (ja) 2017-12-20
PE20180801A1 (es) 2018-05-09
TW201726161A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
IL291554A (en) Administration of therapeutic agents to the central nervous system
HK1218719A1 (zh) 治療試劑的 遞送
HRP20181615T1 (hr) Terapijsko sredstvo koje izaziva citotoksičnost
HK1216105A1 (zh) 治療劑的遞送
GB201114212D0 (en) Therapeutic agents
HK1210416A1 (en) Bioerodible silicon-based devices for delivery of therapeutic agents
GB201119401D0 (en) Therapeutic agents
EP2694076A4 (en) NASAL FORMULATIONS FROM BENZODIAZEPINE
SI2588130T1 (sl) Dostava terapevtskih sredstev v CNS
GB201019938D0 (en) Determination of therapeutic agents
GB201014963D0 (en) Therapeutic agents
GB201012100D0 (en) Therapeutic agents
GB201012101D0 (en) Therapeutic agents
GB201012102D0 (en) Therapeutic agents
GB201010582D0 (en) Therapeutic agents
GB201010577D0 (en) Therapeutic agents
GB201010583D0 (en) Therapeutic agents
GB201003727D0 (en) Therapeutic agent
GB201009614D0 (en) Therapeutic use of compounds
GB201115558D0 (en) Therapeutic agents
GB201110614D0 (en) Therapeutic agents
GB201101128D0 (en) Therapeutic agents
GB201004480D0 (en) Therapeutic use of new compounds II